文献速递主动脉疾病

单一三级中心16年间腹主动脉瘤破裂治疗从开放修复向腔内修复的转变

Transition from Open Repair to Endovascular Aneurysm Repair for Rupture Aortic Aneurysms throughout a 16-Year Period of Time in a Single Tertiary Center.
PubMed 文献 · Ann Vasc Surg · 2023-12-26

该研究回顾性分析2006至2023年单一三级中心收治的200例肾下或近肾破裂性腹主动脉瘤患者,评估逐步将破裂性EVAR作为首选方案的过程。16年间EVAR使用比例从21%升至83%,30天死亡率在初始期46%、中间期64%、当前期35%,当前期EVAR为25%而OSR为83%。作者认为EVAR作为首选可明显降低30天死亡率,且超过80%的破裂性腹主动脉瘤患者可行EVAR。

要点

  • 16年间EVAR占破裂性腹主动脉瘤治疗的比例由21%升至83%。
  • 当前期30天死亡率EVAR为25%而OSR为83%。
  • 作者认为EVAR作为首选可明显降低30天死亡率。

核心结论

  • 在16年期间,将EVAR作为破裂性腹主动脉瘤的首选治疗而非OSR,使30天死亡率出现明显下降。
  • 破裂性EVAR在超过80%的破裂性腹主动脉瘤患者中可行。

研究设计与样本

  • 对前瞻性收集的临床数据进行回顾性分析,纳入2006至2023年因肾下或近肾破裂性腹主动脉瘤接受OSR或EVAR的全部患者。
  • 共200例患者接受破裂性腹主动脉瘤治疗,其中52%经腔内方式(EVAR 94例、Ch-EVAR 9例、分支型腔内动脉瘤修复1例),48%接受OSR(96例)。
  • 分为三个时期:初始期(2006-2011年)、中间期(2012-2017年)和当前期(2018-2023年)。
  • 初始期61例接受治疗(EVAR 21% vs OSR 79%),中间期68例(EVAR 47% vs OSR 53%),当前期71例(EVAR 83% vs OSR 17%)。

主要发现

  • 仅当前期有近肾破裂性腹主动脉瘤经腔内方式治疗(14%)。
  • 30天死亡率初始期为46%(EVAR 31% vs OSR 50%),中间期为64%(EVAR 46% vs OSR 80%),当前期为35%(EVAR 25% vs OSR 83%)。
  • 平均随访时间两组无差异(EVAR 28.3±2个月 vs OSR 33.1±3个月,P=0.56)。
  • 生存率两组无差异:rEVAR在12、24、36、48个月分别为82%(SE 5%)、74%(SE 6%)、68%(SE 6.5%)、63%(SE 7.7%);OSR在6、24、48个月分别为76%(SE 7%)、66%(SE 8%)、56%(SE 9.5%)(P=0.544)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular aneurysm repair (EVAR) is recommended as the first option for both elective and ruptured abdominal aortic aneurysms (rAAAs) with suitable anatomy. The aim of this study was to evaluate the outcomes of the gradual adoption of ruptured EVAR (rEVAR) as first option in the management of rAAAs in a reference tertiary center over a 16 year-period. METHODS: A retrospective analysis of prospectively collected clinical data was undertaken, including all patients that were treated for rAAA infrarenal or juxtarenal either with open surgical repair (OSR) or EVAR from 2006-2023. Three periods were identified and analyzed: Initial (2006-2011); intermediate (2012-2017); and current (2018-2023). The primary outcomes were the 30-day mortality rate in relation to the changing pattern of treatment. Secondary outcomes were re-intervention and mortality during the follow up period. RESULTS: Two hundred patients were treated for rAAA; 52% by endovascular means [EVAR (94), Ch-EVAR (9), and branched endovascular aneurysm repair (1)] and 48% by OSR (96). In the initial period, 61 patients were treated for rAAA (21% EVAR vs. 79% OSR), 68 in intermediate patients (47% EVAR vs. 53% OSR), and 71 in current period (83% EVAR vs. 17% OSR). Only in the current period juxta -renal rAAAs were treated by endovascular means (14%). The 30-day mortality rate was 46% in initial period (31% for EVAR vs. 50% for OSR), 64% in second period (46% in EVAR vs. 80% for OSR), and 35% in third period (25% for EVAR vs. 83% for OSR). The mean follow up did not differ between the groups, (EVAR 28.3 ± 2 months, vs. OSR 33.1 ± 3 months, P = 0.56). The survival rate did not differ between the groups; in rEVAR was 82% (SE 5%), 74% (SE 6%), 68% (SE 6.5%), and 63% (SE 7.7%) at 12, 24, 36, and 48 months, respectively, and in OSR was 76% (SE 7%), 66% (SE 8%), and 56% (SE 9.5%) at 6, 24, and 48 months, respectively (P = 0.544). CONCLUSIONS: Through a 16-year period, the implementation of EVAR as treatment of choice for rAAAs over OSR resulted in a noticeable reduction in the 30-day mortality. rEVAR was feasible in over 80% of rAAA patients.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Spanos K, Volakakis G, Kouvelos G, et al. Transition from Open Repair to Endovascular Aneurysm Repair for Rupture Aortic Aneurysms throughout a 16-Year Period of Time in a Single Tertiary Center. Ann Vasc Surg. 2023. PMID: 38154496. doi:10.1016/j.avsg.2023.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。